Neonatal Purpura Fulminans

What is Neonatal Purpura Fulminans?

Neonatal purpura fulminans is a rare and serious blood clotting disorder that affects newborn babies. It happens when the body forms blood clots in small blood vessels throughout the skin and other organs. These clots block normal blood flow and cause areas of skin to die, creating dark purple or black patches.

This condition is caused by a severe deficiency of Protein C, a natural substance in blood that prevents clots from forming too easily. Babies with neonatal purpura fulminans inherit two copies of a faulty gene, one from each parent. Without enough Protein C, the blood clots too much and too quickly. This leads to dangerous blockages in tiny blood vessels.

The condition appears within hours to days after birth. It requires immediate medical attention and lifelong treatment. Early recognition and treatment can prevent life-threatening complications and help babies grow into healthier children.

Protein C Activity

Checks blood's clotting ability.
Measures protein for clot prevention.
Monitors risk of blood clots.

^$649

Symptoms

Large purple or black patches on the skin that appear soon after birth
Skin areas that look bruised or discolored, often on the limbs or buttocks
Skin tissue that begins to die or develop open wounds
Fever or signs of infection
Difficulty feeding or appearing unwell
Excessive bleeding from the umbilical cord or injection sites
Blood clots in major organs like the eyes or brain
Rapid breathing or other signs of distress

Most babies with this condition show symptoms within the first few days of life. The skin changes are usually the first noticeable sign. Without treatment, the condition progresses rapidly and can become life-threatening.

Causes and risk factors

Neonatal purpura fulminans is caused by inheriting two abnormal copies of the gene that makes Protein C. When both parents carry one faulty gene, their baby has a 25 percent chance of getting both faulty copies. This is called homozygous Protein C deficiency. Without working Protein C, the blood cannot regulate clotting properly. The result is widespread clot formation in small blood vessels.

Risk factors include having parents who are carriers of Protein C gene mutations or having a family history of blood clotting disorders. Consanguinity, when parents are related by blood, increases the chance of inheriting two copies of the same faulty gene. In some rare cases, severe infections in newborns can trigger a similar condition even without genetic deficiency.

How it's diagnosed

Doctors diagnose neonatal purpura fulminans based on the appearance of the skin and specialized blood tests. The key test measures Protein C Activity in the blood. Babies with this condition have very low or undetectable levels of Protein C. Other blood tests check clotting function and look for signs of widespread clot formation throughout the body.

Because this is a rare and specialized condition, diagnosis requires immediate attention from neonatal specialists and hematologists. Genetic testing can confirm the specific mutation causing the Protein C deficiency. Talk to a doctor about appropriate testing if you have a family history of blood clotting disorders and are planning to have children.

Treatment options

Immediate replacement of Protein C through infusions of fresh frozen plasma or Protein C concentrate
Lifelong Protein C replacement therapy to prevent new clots from forming
Blood thinning medications like warfarin once the baby is stable
Wound care for damaged skin areas to prevent infection
Monitoring by a hematologist who specializes in blood disorders
Regular blood tests to check Protein C levels and clotting function
Preventing infections through good hygiene and prompt treatment when illness occurs
Genetic counseling for families to understand inheritance patterns

Frequently asked questions

Neonatal purpura fulminans is caused by inheriting two faulty copies of the gene that produces Protein C, one from each parent. Without enough Protein C, the blood forms dangerous clots in small vessels throughout the body. This leads to skin damage and potential organ complications.

Symptoms typically appear within hours to a few days after birth. The first sign is usually large purple or black patches on the skin. These areas may rapidly progress to skin death if treatment is not started immediately.

There is no cure, but the condition can be managed with lifelong treatment. Babies need regular Protein C replacement therapy and blood thinning medications. With proper treatment started early, many children can live relatively normal lives.

Protein C deficiency follows an autosomal recessive pattern. Both parents must carry one faulty gene copy for a child to develop the severe form. Each pregnancy with two carrier parents has a 25 percent chance of producing an affected baby.

The main diagnostic test measures Protein C Activity in the blood. Babies with neonatal purpura fulminans have very low or undetectable Protein C levels. Additional tests check overall clotting function and look for signs of widespread clot formation.

No, this is an extremely rare condition. It occurs when a baby inherits two copies of a faulty Protein C gene. The condition is more common in families where parents are related by blood or have a known family history of clotting disorders.

Without treatment, neonatal purpura fulminans is life-threatening. The blood clots can damage vital organs including the brain, eyes, and kidneys. Skin tissue dies and can become infected. Immediate treatment with Protein C replacement is necessary to save the baby's life.

Yes, genetic testing can identify parents who carry Protein C gene mutations. Carrier testing is especially important for people with a family history of blood clotting disorders. Genetic counselors can help families understand their risk and available options.

With early diagnosis and proper treatment, many children can survive and grow. They require lifelong Protein C replacement and blood thinning medications. Some may have lasting effects from early skin or organ damage, but proactive care improves outcomes significantly.

Treatment frequency varies based on each child's needs and response to therapy. Some children need Protein C infusions every few days, while others may need them less often. Regular blood tests help doctors adjust the treatment schedule to keep levels safe.